SOX11 and endometrial carcinoma: Sernbo et al. compared SOX11 expression and clinicopathological data in a cohort of 154 primary invasive epithelial ovarian cancer cases of several histological types, including mucinous and endometrial carcinoma, and suggested that SOX11 expression was associated with improved survival of patients with high-grade, mostly endometrioid epithelial ovarian cancer, depending on cancer stage [34].